Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RNA interference

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: RNA interference. Displaying page 1 of 1.
    EudraCT Number: 2014-002212-16 Sponsor Protocol Number: CAIN457ADE03 Start Date*: 2015-01-22
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001415-90 Sponsor Protocol Number: MO42720 Start Date*: 2022-12-12
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: INTERVENTIONAL PLATFORM STUDY INVESTIGATING THE IMPACT OF DIGITAL HEALTH SOLUTIONS ON HEALTH OUTCOMES AND HEALTH-CARE RESOURCE UTILIZATION IN PARTICIPANTS RECEIVING SYSTEMIC TREATMENT IN CLINICAL P...
    Medical condition: Cohort A: ●Metastatic non-small cell lung carcinoma (mNSCLC) ●Extensive-stage small-cell lung carcinoma (ES-SCLC) ●Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: Resected Stag...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025064 Lung carcinoma LLT
    21.0 100000004864 10036706 Primary liver cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003078-33 Sponsor Protocol Number: QRK306 Start Date*: 2016-04-13
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death ...
    Medical condition: QPI-1002 is being developed for the prevention of Delayed Graft Function in patients receiving renal transplants. The patient population of the current study will include patients undergoing deceas...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10076664 Delayed graft function PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) BE (Completed) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000757-49 Sponsor Protocol Number: QRK309 Start Date*: 2018-12-05
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for A...
    Medical condition: QPI-1002 is being developed for prevention of acute kidney injury (AKI) in patients at risk for AKI following cardiac surgery and for reduction in the incidence and severity of delayed graft functi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020989-20 Sponsor Protocol Number: QRK.006 Part B Start Date*: Information not available in EudraCT
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patie...
    Medical condition: I5NP is being developed for the prophylaxis of delayed graft function (DGF) in patients receiving renal transplants. The patient population of the current study will include patients undergoing dec...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10022117 - Injury, poisoning and procedural complications 10048747 Renal graft function delayed LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003113-15 Sponsor Protocol Number: QRK209 Start Date*: 2016-08-02
    Sponsor Name:Quark Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI following Ca...
    Medical condition: QPI-1002 is being developed for prevention of acute kidney injury (AKI) in patients at risk for AKI following cardiac surgery and for reduction in the incidence and severity of delayed graft functi...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:05:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA